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Summary
B chronic lymphocytic leukemia (B-CLL) is characterized by the accumulation of slow-dividing
and long-lived monoclonal B cells arrested at the intermediate stage of their differentiation . We
previously showed that interleukin 4 (IL4) not only inhibits but also prevents the proliferation
of B-CLL cells. We report here that IL-4 protects the B-CLL cells from death by apoptosis
(programmed cell death [PCD]) . IL-4 inhibits spontaneous and hydrocortisone (HC)-induced
PCD of highly purified B cells from 12 unselected CLL patients, as shown by sustained cell
viability and lack ofDNA fragmentation . IL1, -2, -3, -5, -6, -7, tumor necrosis factor a, and
transforming growth factor (3 have no protective effect . The in vitro rescue from apoptosis by
IL-4 is reflected by an increased expression of Bcl-2 protein, a proto-oncogene directly involved
in the prolongation of cell survival in vivo and in vitro. Hence, IL-4-treated B-CLL cells express
significantly more Bcl-2 than unstimulated, HC-treated, or fresh B-CLL cells. Furthermore,
subcutaneous injection of IL4 into one CLL patient enhances Bcl-2 protein expression in the
leukemic B cells . These data may suggest that IL-4 prevents apoptosis of B-CLL cells using a
Bcl-2-dependent pathway. Given our recent observations that fresh T cells from B-CLL patients
express IL-4mRNA, we propose that IL-4 has an essential role in the pathogenesis ofCLL disease,
by preventing both the death and the proliferation of the malignant B cells .
Programmed cell death (PCD ;t or apoptosis) is acommon
form of cell deletion that can be activated in different cell
types in response to a number of physiologically relevant
stimuli. This process is usually accompanied by the cleavage
of host chromatin into nucleosome-size fragments of -200
by appearing as a typical ladder pattern (1) . To date, a specific
endonuclease or internucleosomal activity has not been
purified. Triggering ofT cells within the thymus with anti-
CD3 antibodies (2), superantigens (3), or specific peptides
(4), or exposure of the thymocytes to glucocorticoids (5),
leads to apoptosis. In contrast, in the germinal centers oflymph
nodes, the selection of B lymphocytes that produce high-
affinity antibodies is achieved by prevention from apoptosis
for those cells that receive a positive signal after antigen rec-
ognition by their Ig receptors (6) . Similarly, factor-dependent
cell lines undergo apoptosis after disappearance ofthe stimulus,
such as removal of growth factors from hematopoietic
precursors (7) .
Bcl-2 is a unique proto-oncogene that plays an important
1 Abbreviations used in this paper. HC, hydrocortisone; PCD, programmed
cell death .
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role in cell survival . It was first isolated from the breakpoint
of the translocation between chromosomes 14 and 18 fre-
quently found in the neoplastic cells of patients with indo-
lent follicular B celllymphoma (8) . In normal tissues, Bcl-2
expression is topographically confined to the zones of sur-
viving B cells in germinal centers or surviving mature thymo-
cytes in the medulla (9) : Infection with Bcl-2 retrovirus pre-
vents PCD occurring in some pro-B cell lines upon IL-3
deprivation (10) . Gene transfer into several cell types has
confirmed that Bcl-2 acts by inhibiting cell loss rather than
by stimulating cell proliferation (11) .
Bcl-2 cooperates with c-myc to promote proliferation of
B cell precursor (10), and doubly transgenic mice (ew-Bcl-
2/myc) develop tumors much faster than eg-myc mice, sug-
gesting that prolonged B cell life may increase tumor inci-
dence (12) . A similar synergy between Bcl-2 and c-myc has
been extended to T cells in which combined transfer of the
two genes enhances tumorogenicity ofhuman T lymphoid
cell line into athymic mice (13) .
It was recently demonstrated that Bcl-2 enhances T cell
survival using Bcl-2 transgenic mice expressing the transgene
in the T cell lineage (14, 15) . Thymocytes of Bcl-2 trans-
genic strains not only exhibit an increased survival when
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tiple forms ofapoptosis, including treatmentwith glucocor-
ticoids, anti-CD3, andy radiation. Interestingly, clonal de-
letion ofT cells that recognize endogenous superantigens is
still occurring, suggesting the existenceofaBcl-2-independent
pathway.
Chroniclymphocytec leukemia (CLL) is characterized by
the accumulation of monoclonal long-lived B-CLL cells ar-
rested at the intermediate stage of their differentiation (16) .
B-CLL cells enter into apoptosis either spontaneouslywhen
cultured in vitro (17) or after incubation with glucocorti-
coids, Caz+ ionophore, and anti-Ig antibodies (18) . We pre-
viously reported that glucocorticoid hormone (hydrocorti-
sone [HC]) is absolutely required with IL-4 to induce the
differentiation of unfractionated CLL cells into IgE-producing
cells (19) . We therefore examined whether IL-4 would pre-
vent HC-induced PCD in these leukemic cells. Here we re-
port that IL4 inhibits spontaneous and HC-induced apop-
tosis in highly purified B cells from unselected CLL patients
and upregulates their Bcl-2 expression .
Materials and Methods
CLL Samples.
￿
13 CLL patients were examined in the present
study. Their agerangewasfrom 39 to 70 yr. Their peripheral blood
contained 40-90 x 10" leukocytes/mm" of which 60-90% were
lymphocytes . Flow cytometry analysis indicated that their B-CLL
cells coexpressed CD20,CD5, and CD23 ; nine patients were IgM
X and four patients IgM K . Patients 1-7 were at clinical stage Rai
0 (n = 2), Rai I (n = 1), and Rai III (n = 4), and patients 8-12
were at Rai 0 (n = 2) and Rai III (n = 3) . 10 patients were not
receiving therapy at the time of the study. Patients 7 and 10 were
administered oral prednisone for a consecutive 5 d before the study.
Patient 13 (Rai IV) belonged to the preclinical study initiated to
assess the antiproliferative effect of ILA in CLL disease (20) . He
received subcutaneous injections of rIL4 (100/Ag/m2) for a con-
secutive 5 d with no significant side effects .
Cell Separation and Culture Conditions.
￿
PBMC from CLL pa-
tients (>90% CD5 and CD20 positive)were isolated with Lympho
Prep (Cederlane Laboratories, Ontario, Canada) . Highly purified
B cells (no detectable CD3- or CD14-positive cells) were negatively
selected by a combination of rosetting (twice) with aminoethyl-
isothiouronium bromide-treated SRBC, adherence to plastic, and
treatment with L-leucine ester. Highly purified B-CLL cells were
incubated at 2.5 x 106/ml (48-well flat-bottomed plate) in HB101
serum-free medium for a culture period time of 24-48 h . HC
(Sigma Chemical Co., St . Louis, MO), was used at 10-5 M or 5
x 10-4 M according to dose-response curves (Fig . 1) and previ-
ously reported data (18) . Recombinant IL4 was obtained from ei-
ther Genzyme Corp. (Boston, MA) or from Dr. H. Hofstetter
(CIBA-GEIGY, Basel, Switzerland) and wasused at 10 ng/ml final
concentration . Recombinant IM, -2, -3, and -6 were purchased
from Genzyme Corp. IL-5 and TNF-a were from Dr.W . Fiers
(State University, Ghent, Belgium), 11,7 was obtained from Im-
munex Corp. (Seattle, WA), and TGF-02 was from Dr. D . Cox
(CIBA-GEIGY, Basel) . Recombinant soluble CD23 (sCD23) was
prepared in our laboratory. Cell viability wasdetermined by trypan
blue dye exclusion or by staining the cells with propidium iodide
(2 lAg/ml) and analysis by flow cytometry(FACscan® ; Becton Dick-
inson & Co ., Mountain View, CA) .
DNA Fragmentation Assay.
￿
Cells (2.5 x 106/ml) were washed
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twice with PBS and pelleted by centrifugation at 200 g for 5 min
at room temperature .DNA was isolated using a slightly modified
procedure as described (21) . Briefly, cell pellets (2.5 x 106) were
resuspended in cell lysis buffer (10mM EDTA, 50 mM Tris [pH
8], containing 0.5% [wt/vol] N-laurylsarcosine and0.5 14g/ml pro-
teinase K) and incubated for 1 h in a 50°C water bath . RNase
A was then added to a concentration of 0.25 mg/ml and incuba-
tion was prolonged for 1 h at 50°C . TheDNApreparations were
then extracted (twice) with buffered phenol (Sigma Chemical Co .),
followed by two chlorophorm/isoamyl alcohol (24:1) extractions
for removal ofprotein and residual traces ofphenol .DNAprepara-
tions were then brought to 1.5 volby the addition of 10mM Tris-
HCL, pH 8, 1 mM EDTA (TE buffer), and were centrifuged at
14,000 g to separate intact from fragmented chromatin . The su-
pernatants, containing fragmented DNA, were placed in separate
tubes andDNA was precipitated with 0.5-vol ammonium acetate
(2 M) and 2vol of ethanol at -70°C for24h. TheDNAprecipi-
tates were recovered by centrifugation at 13,000 g for 15 min, air
dried for 1 h at room temperature, andresuspended in TE buffer.
Samples were supplemented with loading buffer (0.25% bromo-
phenol blue [wt/vol], 50% glycerol [wt/vol], and 10 mM EDTA)
at a 5:1 ratio and then heated at 65°C for 10 min . Electrophoresis
was carried out in 1% gel at 6 V/cm of gel using TBE buffer
(2 mM EDTA [pH 8], 89 mM Tris, 89 mM boric acid) . A BgI1+
and Hinfl digest of pBR328 DNA (Boehringer Mannheim Bio-
chemicals, Indianapolis, IN)was applied to each gel to provide size
markers. After electrophoresis,DNAwas visualized by soaking the
gel for 30 min in TBEcontaining 1 P,g/ml ethidium bromide and
destained for 30 min in TBE buffer.
Western Blot Analysis ofBcl-2 Protein Expression.
￿
Western blots
were performed as described (22) . Briefly, cell lysates were obtained
by sonicating cells for 20 s and boiling for 5 min in 50 mM Tris
buffer, pH 6.8 with 2% SDS, 2% 2-ME, 10% glycerol, and0.1%
bromophenol blue . Samples containing lysates of 4, 2, or 1 x 106
cells in 20 tt1 were separated by discontinuous electrophoresis on
a10% acrylamide geland blotted onto nitrocellulose filter. Blotted
filters were blocked for2husing a 5% suspension ofdriedskimmed
milk in Tris buffer, pH 7.5 (milk TBS) . The filter was then in-
cubated at 4°C with anti-Bcl-2 mAb (10% supernatant) (kindly
given to us by Dr.D.Y Mason, Headington, Oxford) in 5% milk
TBS. After overnight incubation, the filter was washed and fur-
ther incubated for 1 h at 20°C with 1:5,000 rabbit anti-mouse
Ig (Dako Corp ., Santa Barbara, CA) in 5% milk TBS, washed,
and incubated for 1 h with "'I-labeled protein A (Amersham
Corp ., Arlington Heights, IL) diluted at 0.1 t&Ci/ml in 5% milk
TBS. After further washing, the filter wasexposed from 4 to 48 h.
Quantitative analysis was performed by either cutting the bands
from the filter and counting in a gamma counter (in cpm) or by
scanning densitometry (GS300 ; Hoefer Scientific, San Francisco,
CA) (relative intensity units) . Protein molecular weight standards
(Rainbow TM ; Amersham Corp.) were run with each gel .
Electron Microscopy .
￿
For the morphological studies, the cells were
fixed with 1% glutaraldehyde in 0.1Mphosphate buffer, post-fixed
with 1% osmium tetroxide, andembedded in Epon according to
routine techniques . For electron microscopy, the thin sections were
mounted on nickel grids and examined with an electron micro-
scope (410; Philips Electronics Instruments, Inc., Piscataway, NJ)
staining with uranyl acetate and lead citrate .
Results
IL4 Rescues B-CLL Cells from Their Entry into Apop-
tosis.
￿
We first show that HC significantly decreases cell via-Table 1 .
￿
IL-4 Prevents HC-induced Apoptosis ofB-CLL Cells
Percent viability from :
Patient
￿
Medium
￿
IL-4
￿
HC
￿
IL-4+HC
B-CLL cells were cultured (2 .5 x 10 6/ml) in the absence or presence
of IL-4 (10 ng/ml) supplemented or not with HC (10 -5 M) . After
24 h (patients 1-3) or 48 h (patients 4-7), cell viability (%) was deter-
mined by trypan blue dye exclusion .
bility ofhighly purifiedB cells isolated from unselected CLL
patients (n = 7), as determined by trypan blue dye exclu-
sion, and that this effect is completely prevented by IL4 (Table
1) . Maximal HC-induced cell death is obtained after a 2-d
culture (Fig. 1 A), and IL4 exerts its protective effect from
day 1 to 3 . This protective effect may be prolonged until day
5 (not shown) . The concentrations of HC (5 x 10 -4 M)
and IL4 (10 ng/ml) used throughout the study have been
selected on the basis of dose-response curves (Fig . 1, B and
C) and of our previous report indicating that B-CLL cells
differentiate into IgE-secreting cells under these conditions
(19) . Morphological examination of the HC-treated B-CLL
cells at the electron microscope (Fig . 2) demonstrates the oc-
currence of apoptotic cells at different stages . Also, the typ-
ical "ladder" DNA degradation observed during the process
of apoptosis upon exposure to HC totally disappears in the
presence of IL-4 (Fig . 3), indicating that IL4 rescues B-CLL
cells from apoptotic death . B-CLL cells are next stained with
propidium iodide to quantitate cell death . As shown in Fig.
4, brightly stained cells (FL3 positive) are dead cells, while
cells with reduced forward scatter likely represent those en-
tering apoptosis that have not started to take up trypan blue.
Our results clearly show that IL4 treated cultures (in the
presence or absence of HC) contain virtually no dead cells
and a low proportion of cells with reduced forward scatter,
further demonstrating that IL-4 completely abrogates spon-
taneous or HC-induced PCD . Hence, some B-CLL clones
may undergo spontaneous PCD after in vitro culture (17) .
IL-4 sustains cell viability of these particular B-CLL cells (n
= 5) (Table 2, and Figs. 1 and 4) without inducing cell divi-
sion and proliferation (M . Sarfati, personal observations) . IL-4
prevents the spontaneous DNA fragmentation occurring in
these B-CLL clones (not shown) . We next show that IL-1 ,
-2, -3, -5, -6, -7, TNF-(x, and TGF-,(3 have no protective effect
on HC-induced PCD in B-CLL cells (Fig. 5) . In contrast
to normal germinal centerB cells (23), CD23 in the presence
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or absence ofIL1a does not significantly rescueB-CLL cells
from apoptosis. Finally, the antiapoptotic effect ofIL-4 is abol-
ished by neutralizing anti-I1,4 mAb (not shown) .
11,4 Upregulates Bcl-2 Protein Expression in B-CLL Cells.
B-CLL cells from the great majority of patients express Bcl-2
0
0
z
3.5
3.0 -
2.5 -
2.0 -
1 .5 -
1 .0 -
0.5
DAYl DAY2 DAYS
Medium
IL4
HC
ItCi IL4
Figure 1 .
￿
Kinetic studies of HC-induced cell death in B-CLL cells (A)
and dose-related effects ofHC (B) andIL4 (C) . B-CLL cells from patient
11 were cultured (2 .5 x 106/ml) for 1, 2, or 3 d in the absence or pres-
ence ofHC (5 x 10-4 M) with or without IL4 (10 ng/ml) (A); in the
absence or presence of various concentrations of HC for 2 d (B) ; with
HC (5 x 10 -4 M) for 2 d in the absence or presence of various concen-
trations of 11,4 (C) . At the end of the culture, the number ofviable cells
was counted in duplicate using trypan blue dye exclusionmethod . Shown
is one representative patient out of two.
1 96 .3 98 .5 57 .2 95.9
2 93 .6 97.3 51 .6 90.5 A
3 95 .6 98.3 67 .7 92.4
4 83 .0 86.0 41 .0 81.4
5 94.4 97.2 40 .4 96.7 x
6 77.5 ND 57 .0 76 .5
m
7 84.0 82.8 63 .0 81 .0 U
N
ccFigure 2 .
￿
Electron microscopy of apoptic cells in HC-treated B-CLL cell cultures. B-CLL cells (2 .5 x 106/ml) from patient 5 were cultured with
HC (5 x 10-4 M) for 2 d . Morphological view of the cells at electron microscope (x15,000) demonstrating the presence of normal cells (filled arrows)
together with cells at different stages of apoptosis (open arrows) .
(24, 25), a proto-oncogene encoding an inner mitochondrial
membrane protein directly involved in the prevention of apop-
totic cell death (26) . As shown in Fig . 6, Bcl-2 expression
drastically decreases in B-CLL cells incubated with HC but
not in IL-4- and HC-treated cultures. Also, IL4-treatedB-CLL
cells express more Bcl-2 than unstimulated B-CLL cells, sug-
gesting that the rescue from apoptosis by IL4 is reflected by
a sustained Bcl-2 expression .
We next examine whether IL4 is capable of upregulating
Bcl-2 protein in the leukemic cells by comparing Bcl-2 ex-
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Figure 3 . 11,4 inhibits HC-
induced DNA fragmentation in
B-CLL cells. B-CLL cells from pa-
tient 5 were cultured for 24 h .
(Lane 1) Molecular size markers ;
(lane 2) unstimulated cultures ;
(lane3) 11,4-treated cultures ; (lane
4) HC-treated cultures ; and (lane
5) IL4 and HC-treated cultures .
Shown is one representative pa-
tient out of three.
pression of freshly isolatedB-CLL cells with that ofB-CLL
cells incubated for 24 h in the presence of IL4 . Quantitative
analysis indicates that ILA significantly upregulates the level
ofBcl-2 protein expression inB-CLL cells when gels are loaded
with lysates of 1, 2, and 4 x 106 B-CLL cells (Fig. 7) (mean
± SEM for two CLL patients : 11,270 ± 3,416 cpm [fresh
B-CLLs] ; 14,208 ± 3,849 cpm [IL4-treated B-CLLs] ; p =
0.003, paired Student's t test) . Finally, and most interestingly,
subcutaneous administration of IL4 (100 Ug/m2 ) into one
B-CLL patient (Rai IV) augments Bcl-2 protein expression
Table 2 .
￿
IL-4 Prevents Spontaneous Apoptosis ofB-CLL Cells
Percent viability
Patient
￿
Medium
￿
IL-4
8
￿
69 .9
9
￿
59 .0
10
￿
33 .7 (0.8)
11
￿
74.3 (1 .7)
12
￿
77 .0 (1 .3)
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95.3
82.0
89.7 (2.6)
98.6 (2.5)
97.0 (2.1)
B-CLL cells were cultured (2.5 x 10 6/ml) in the absence or presence
of IL-4 (10 ng/ml) . After 48 h, cell viability (%) was determined by
trypan blue dye exclusion . Number of viable cells (x 106 ) is shown in
parenthesis .Figure 4 .
￿
Flow cytometry analysis of HC-induced apoptosis in B-CLL
cells and of 11,4 protective effect . B-CLL cells (2 .5 x 106/ml) from pa-
tient 11 were cultured in the absence or presence of HC (5 x 10-4 M)
with or without 11,4 (10 ng/ml) . After 2 d, cells were stained with
propidium iodide (2 pg/ml) to show dead cells (FL3 fluorescence) . Shown
is one representative experiment out of five.
in their B cells, strongly supporting the view that IL4 is in-
deed capable of upregulating Bcl-2 expression in the malig-
nant B cells (Fig . 8) . Of note, the efficacy of IL-4 administra-
tion is substantiated by a parallel increase in surface CD23
expression (from 23 to 98% CD23-positive cells) in the same
leukemic B cells .
Figure 5 .
￿
The rescue of B-CLL cells from apoptic death is restricted
to 11,4 . B-CLL cells from patient 9 were cultured for 48 h in the absence
or presence ofHC (5 x 10-4 M) with or without11 .1a (1 ng/ml), IL2
(20 U/ml), I1r3 (10 ng/ml), 114 (10 ng/ml),11r5 (1/500), IL6 (500 U/ml),
I1r7 (1,000 U/ml), TGF-0 (2 ng/ml), TNF-ot (25 ng/ml), sCD23 (25
ng/ml), or sCD23 and II,1ot . B-CLL cells were also incubated with 114
in the absence of HC. Shown is one representative patient out of two.
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Discussion
ILA is a T cell-derived multifunctional cytokine, origi-
nally described asB cell stimulatory factor (BSF-1), for normal
preactivated human and mouse B cells (27) . We and others
recently reported that ILA is a very potent antiproliferative
agent for B-CLL cells by showing that IL4 not only blocked
but also prevented the proliferation of the leukemic B cells
to various stimuli (i.e., IL-2, IFN-cx, TNF-a, and low mo-
lecular weight B cell growth factor) (28, 29) . In this report,
we present a novel function for IL4 in CLL, in that IL4 pro-
tects B-CLL cells fromprogrammed cell death . IL4 prevents
both glucocorticoid-induced and spontaneous apoptosis in
B-CLL cells, as shown by sustained cell viability (trypan blue
exclusion and flow cytometry) and absence ofDNA frag-
mentation in B-CLL cells cultured in the presence of IL4 .
The high degree of variability in the amount of spontaneous
or HC-induced cell death observed in different CLL samples
is in keeping with previous reports (17, 18) and is not cor-
related with the phenotype oftheB-CLL clones (not shown) .
The effect of IL4 is specific as it is overcome by anti-IL4-
a.
24000
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12000
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8000
6000
4000
2000
0
Day 0
￿
Day I+IL4
Figure 6 .
￿
IL4 sustains Bd-2 ex-
pression in B-CLL cells . B-CLL
cells from patient 4 were cultured
(2 .5 x 106/ml) in medium (lane
1) supplemented with 11,4 (lane
2),HC (10-5M) lane 3), or 11,4
andHC (lane 4) . After 24 h, equal
amounts of cell lysates (2 x 106
cells) were separated on a 10%
SDS-PAGE gel . Immunoblot for
the detection ofBcl-2 protein (25
K) followed by autoradiography
(48-h exposure) was performed as
described in Materials and Meth-
ods. Shown is one representative
patient out of three .
p<0.003
Figure 7 .
￿
114 upregulatesBcl-2protein in B-CLL cells in vitro. Immu-
noblot for the detection of Bcl-2 protein was carried out with B-CLL
cells from patients 1 and 2 . Cell lysates of 1 x 106 ( . . .
￿
), 2 x 106
(
￿
), and 4 x 106 (- - - -) cells were prepared from freshly isolated
B-CLL cells (day 0) or B-CLL cells incubated with 114 (10 ng/ml) for
24 h (day 1 + IL4), and separated on a 10% SDS-PAGE . After immuno-
blotting andhybridization, bands were cut and countedin a gamma counter.neutralizing mAb (not detailed) . Moreover, IIJ1, -2, -3, -5,
-6, -7, TNF-a, and TGF-/3 have no protective effect .
The ability of IIA to rescue B-CLL cells from apoptosis
contrasts with its lack of protective effect on spontaneous
PCD of germinal center B cells (6), on ionomycin-induced
apoptosis of tonsillar B cells (30), or on apoptosis of group
I Burkitt lymphoma cells (31) . It is relevant to note that IL4
also inhibits ionomycin-inducedPCD in B-CLL cells as well
as in umbilical cord blood B cells (M . Sarfati, personal obser-
vations), strongly suggesting that the protective effect of IL-4
ismore related to the biology of theB-CLL cell or its normal
cellular counterpart rather than to the pathways used to in-
duce its apoptosis . In opposition to B-CLL cells, IL-2 blocks
ionomycin-induced apoptosis in normal B cells (30) . Simi-
larly, CD23 in combination with IL1ot rescue germinal center
B cells (centrocytes) from their entry into apoptosis (23),
whereas they have only a slight effect on B-CLL cells, sug-
gesting that IL4 does not mediate its protective effect via
the upregulation ofCD23 . Supporting this view, anti-CD23-
neutralizing mAb does not inhibit the IL-4 rescue pathway
(M . Sarfati, personal observations) .
Occupancy of the surface Ig receptor for antigen protects
centrocytes from PCD (6), whereas it induces PCD in normal
tonsillar B cells, B-CLL cells (18), and in B lymphoma cell
lines (32), leading to the notion that the ability to induce
apoptotic cell death may depend on the differentiation stage
of the B cell . Signaling through CD40 antigen also prevents
cell death in both centrocytes and Burkitt lymphoma cell lines
(6, 23) . However, anti-CD40 has no protective effect inB-CLL
cells (not shown) . So far, the onlycommon agent described,
capable ofpreventingPCD in both normal and leukemic CLL
B cells, is PMA, an activator of protein kinase C (PKC) (18,
30) . These observations suggest that activation of PKC is
a common pathway to desensitize the cells to PCD . Hence,
PMA also prevents apoptotic cell death in human thymo-
cytes incubated with anti-CD3 antibodies (33) . Finally, acti-
vation ofEBVlatent genes protects human B cells from apop-
totic death (31) . This protective effect has been recently
attributed to the latent membrane protein(IMP 1) (34) . Most
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Figure 8 .
￿
IIA upregulates Bcl-2
protein in B-CLL cells in vivo.
B-CLL cells were isolated from pa-
tient 13, before and 5 d after subcu-
taneous administration of IIA
B-CLL cells were stained with anti-
CD23-PEmAb (Becton Dickinson
& Co .) for CD23 expression (left) .
Detection of Bcl-2 protein by im-
munoblotting and hybridization
was carried out with 2 x 106 cell
lysates (lane 1, before treatment ;
lane 2, 5 d after treatment) . Au-
toradiograph was scanned by den-
sitometry, and results are expressed
as units of relative intensity (right) .
interestingly, IMP 1 prevents PCD by directly inducing Bcl-2
protein .
Bcl-2 is unique among proto-oncogenes, being localized
in the inner mitochondrial membrane and extending cell sur-
vival by inhibiting programmed cell death (26) . The Bcl-2
gene was first discovered at the breakpoint of the transloca-
tion between chromosomes 14 and 18 (t [14;18]) found in
most follicular B cell lymphomas and some diffuse large cell
lymphomas (8) . It was also reported that the rearrangement
of the Bcl-2 gene occurs in a significant fraction (10%) of
B-CLLs, with a preferential linkage to the Ig light chain gene
(35) . However, recent reports indicate that most follicular
and diffuse lymphomas, as well as allCLL cases lacking Bcl-2
rearrangement, display intense to intermediate Bcl-2 staining
(24, 25), suggesting that mechanisms other than classic trans-
location may be deregulating Bcl-2 expression .
Our present study shows that the protective effect of IL4
is associated with an enhanced Bcl-2 expression in the leu-
kemic B cells . Of note, activation of centrocytes by signals
that prevent their entry into apoptosis (i.e., anti-CD40 mAb,
or sCD23 and IL-1) also induces Bcl-2 expression (22) . Our
data indicate that various levels of Bcl-2 expression are ob-
served in freshB cells from all CLL cases examined . Neverthe-
less, IL4-treated B-CLL cells express significantly more Bcl-2
protein than freshly isolated, unstimulated, or HC-treated
B-CLL cells, indicating that IIA upregulates Bcl-2 in vitro .
Interestingly enough, subcutaneous injection ofIL4 into one
B-CLL patient (Rai IV) upregulates Bcl-2 expression in the
leukemic B cells. Recent studies have shown that glucocor-
ticoid-induced apoptosis in the thymus is Bcl-2 dependent,
while clonal deletion appears to be Bcl-2 independent (14,
15) . We therefore propose that IL4 inhibits HC-induced PCD
ofB-CLL cells via their upregulation ofBcl-2 without ruling
out the existence of an independent pathway.
Given our recent observations that freshly isolated T CLL
cells, which are comprised of a very low ratio of CD4+/
CD8+ cells, express the IL4 gene (36) and that HC sup-
presses IL4 production by activated normal T cells (37), the
glucocorticoid-induced PCD in CLL may be explained bya direct effect ofHC onB-CLL cellscombined with its ability
to suppress the IL -4 gene inTCLL cells . Finally, with CLL
being characterized by the accumulation of long-lived ab-
normal B cells with a very low proliferative index, it is
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